EMulate Therapeutics’ manuscript, “Magnetic Field Emulations of Small Inhibitor RNA: Effects on GL261 Tumors,” has been accepted for publication in the Open Journal of Biophysics. The paper showcases EMulate’s second signal treatment, A2, in a Glioblastoma Multiforme (GBM) animal model. GBM, a rare and aggressive brain tumor, has no established treatment and falls under the FDA’s orphan disease category.
A2 targets immune checkpoint inhibitors target CTLA-4 and PD-1, suppressing their expression and inhibiting tumor growth in the mouse model. These findings corroborate an earlier study by Mukthavaram et al. and support the positive outcomes of EMulate’s Phase I clinical trial (NCT02507102), indicating safety and potential efficacy against GBM in humans.
EMulate’s SVP of Pre-Clinical Development, Dr. Xavier Figueroa, highlights the promising potential of their technology, ulRFE, in treating cancers and other diseases with significant unmet medical needs. EMulate aims to confirm these benefits in future clinical trials further.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
